APA (7th ed.) Citation

B, S., D, R., MP, E., J, S., A, K., WE, B., . . . D, S. (2017). Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: A multicenter, randomized phase IIb study. Annals of oncology : official journal of the European Society for Medical Oncology, 28(10), 2429. https://doi.org/10.1093/annonc/mdx343

Chicago Style (17th ed.) Citation

B, Schultheis, et al. "Gemcitabine Combined with the Monoclonal Antibody Nimotuzumab Is an Active First-line Regimen in KRAS Wildtype Patients with Locally Advanced or Metastatic Pancreatic Cancer: A Multicenter, Randomized Phase IIb Study." Annals of Oncology : Official Journal of the European Society for Medical Oncology 28, no. 10 (2017): 2429. https://doi.org/10.1093/annonc/mdx343.

MLA (9th ed.) Citation

B, Schultheis, et al. "Gemcitabine Combined with the Monoclonal Antibody Nimotuzumab Is an Active First-line Regimen in KRAS Wildtype Patients with Locally Advanced or Metastatic Pancreatic Cancer: A Multicenter, Randomized Phase IIb Study." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 28, no. 10, 2017, p. 2429, https://doi.org/10.1093/annonc/mdx343.